Items Tagged ‘ipilimumab’

September 28, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma


Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European Society for Medical Oncology and published simultaneously in the New England Journal of Medicine. There remains an unmet need for […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, nivolumab, opdivo, Precision Cancer Medicine, Yervoy